SyneuRx Neuroscience is developing new-generation treatment for depression and dementia by targeting the N-methyl-D-aspartate receptor (NMDAR) in the glutamate system—the most abundant system in the brain—rather than the traditional monoamine system (dopamine/serotonin/norepinephrine receptors).

SN holds 4 clinically validated assets in Depression and Dementia. Our current priority is to raise fund to advance the phase 2b and phase 3 clinical studies for the treatment of Depression.